Points of concern related to the micafungin versus caspofungin trial

Clinical Infectious Diseases

Volumn 46, Issue 4, 2008, Pages 640-641

  Eiland, Edward H ^a   Hassoun, Ali ^a   English, Thomas ^b  

^a HUNTSVILLE HOSPITAL   (United States)

^b UNIVERSITY OF ALABAMA IN HUNTSVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPROTEIN;

CANDIDA PARAPSILOSIS; CLINICAL TRIAL; DIABETIC PATIENT; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FUNGUS CULTURE; HUMAN; INFECTION RISK; INVASIVE CANDIDIASIS; LETTER; PRIORITY JOURNAL; SURGICAL TECHNIQUE; UNITED STATES; CANDIDA; CANDIDIASIS; CLASSIFICATION; COMPARATIVE STUDY; DRUG EFFECT; NOTE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; ECHINOCANDINS; HUMANS; LIPOPROTEINS;

EID: 38849149866     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/527036     Document Type: Letter

References (8)

1. Pappas PG, Rotstein CM, Betts RF. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883-93.
2. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-89.
3. Marco F, Pfaller MA, Messer SA, Jones RN. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis 1998; 32:33-7.
4. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950-6.
5. Moore CB, Oakley KL, Denning DW. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect 2001; 7:11-6.
6. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK 463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44:57-62.
7. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20:133-63.
8. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence of echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 2007; 51:2257-9.